Iveric Bio stock price was trading at 1$ in 2019. It was bought for 38$ this morning (5.9B$).
We have excellent data, no matter how you slice it. There's no reason that DR above 30% @450-days doesn't lead to Breakthrough stays as it means we have data that is superior to competition. This is all verifiable. Not something made up because we want to get rich. Simply because comparable data is out there for us to assess where we stand.
ScienceFirst - (5/1/2023 9:09:39 AM)
Buyout before a FDA decision
After GSK's 2B$US move on BELLUS that was 2y before FDA approval, here's another example of a pharmas making a move 3 months before a FDA decision:
Astellas keeps the big buyouts rolling, inking $5.9B Iveric takeover ahead of FDA eye disease ruling
By Nick Paul Taylor May 1, 2023 08:13am
The multibillion-dollar biotech buyouts keep on coming. Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche.
Iveric is less than three months away from learning whether the FDA will approve avacincaptad pegol